Skip to content

In the BioHarmony Drug Report Database

Eptinezumab

Vyepti (eptinezumab) is an antibody pharmaceutical. Eptinezumab was first approved as Vyepti on 2020-02-21. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1 and calcitonin gene-related peptide 2.
Trade Name Vyepti
Common Name Eptinezumab
Indication
Drug Class Monoclonal antibodies: humanized, neural indications
Eptinezumab
Get full access now